Patent application number | Description | Published |
20090169505 | NOVEL VACCINES AGAINST MULTIPLE SUBTYPES OF INFLUENZA VIRUS - An aspect of the present invention is directed towards DNA plasmid vaccines capable of generating in a mammal an immune response against a plurality of influenza virus subtypes, comprising a DNA plasmid and a pharmaceutically acceptable excipient. The DNA plasmid is capable of expressing a consensus influenza antigen in a cell of the mammal in a quantity effective to elicit an immune response in the mammal, wherein the consensus influenza antigen comprises consensus hemagglutinin (HA), neuraminidase (NA), matrix protein, nucleoprotein, M2 ectodomain-nucleo-protein (M2e-NP), or a combination thereof. Preferably the consensus influenza antigen comprises HA, NA, M2e-NP, or a combination thereof. The DNA plasmid comprises a promoter operably linked to a coding sequence that encodes the consensus influenza antigen. Additionally, an aspect of the present invention includes methods of eliciting an immune response against a plurality of influenza virus subtypes in a mammal using the DNA plasmid vaccines provided. | 07-02-2009 |
20100166787 | VACCINES AND METHODS FOR USING THE SAME - Improved anti-HIV immunogens and nucleic acid molecules that encode them are disclosed, Immunogens disclosed include those having consensus sequences for HIV Subtype A Envelope protein, those having consensus sequences for HIV Subtype B Envelope protein, those having consensus sequences for HIV Subtype C Envelope protein, those having consensus sequences for HIV Subtype D Envelope protein, those having consensus sequences for HIV Subtype B consensus Nef-Rev protein, and those having consensus sequences form HIV Gag protein subtypes A, B, C and D. Improved anti-HPV immunogens and nucleic acid molecules that encode them; improved anti-HCV immunogens and nucleic acid molecules that encode them; improved hTERT immunogens and nucleic acid molecules that encode them; and improved anti-Influenza immunogens and nucleic acid molecules that encode them are disclosed. Pharmaceutical composition, recombinant vaccines comprising and live attenuated pathogens are disclosed as well methods of inducing an immune response in an individual against HIV, HPV, HCV, hTERT and Influenza are disclosed. | 07-01-2010 |
20100189730 | VACCINES FOR HUMAN PAPILLOMA VIRUS AND METHODS FOR USING THE SAME - Improved anti-HPV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HPV 18 E6 and E7. Pharmaceutical composition, recombinant vaccines comprising and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HPV are disclosed. | 07-29-2010 |
20110182938 | INFLUENZA NUCLEIC ACID MOLECULES AND VACCINES MADE THEREFROM - Provided herein are nucleic acid sequences that encode novel consensus amino acid sequences of HA hemagglutinin, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an immune response against one or more Influenza A serotypes using the vaccines that are provided. | 07-28-2011 |
20110184160 | NUCLEIC ACID MOLECULE ENCODING CONSENSUS INFLUENZA A HEMAGGLUTININ H1 - Provided herein are nucleic acid sequences that encode novel consensus amino acid sequences of HA hemagglutinin, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an immune response against one or more Influenza A serotpyes using the vaccines that are provided. | 07-28-2011 |
20110305664 | NOVEL VACCINES AGAINST MULTIPLE SUBTYPES OF INFLUENZA VIRUS - An aspect of the present invention is directed towards DNA plasmid vaccines capable of generating in a mammal an immune response against a plurality of influenza virus subtypes, comprising a DNA plasmid and a pharmaceutically acceptable excipient. The DNA plasmid is capable of expressing a consensus influenza antigen in a cell of the mammal in a quantity effective to elicit an immune response in the mammal, wherein the consensus influenza antigen comprises consensus hemagglutinin (HA), neuraminidase (NA), matrix protein, nucleoprotein, M2 ectodomain-nucleo-protein (M2e-NP), or a combination thereof. Preferably the consensus influenza antigen comprises HA, NA, M2e-NP, or a combination thereof. The DNA plasmid comprises a promoter operably linked to a coding sequence that encodes the consensus influenza antigen. Additionally, an aspect of the present invention includes methods of eliciting an immune response against a plurality of influenza virus subtypes in a mammal using the DNA plasmid vaccines provided. | 12-15-2011 |
20120034256 | HCV VACCINES AND METHODS FOR USING THE SAME - Improved anti-HCV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HCV genotype 1 a/1 b NS3 and NS4A. Pharmaceutical composition, recombinant vaccines comprising and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HCV are disclosed. | 02-09-2012 |
20120064116 | INFLUENZA NUCLEIC ACID MOLECULES AND VACCINES MADE THEREFROM - Provided herein are nucleic acid sequences that encode novel consensus amino acid sequences of HA hemagglutinin, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an immune response against one or more Influenza A serotypes using the vaccines that are provided. | 03-15-2012 |
20120093863 | HCV VACCINES AND METHODS FOR USING THE SAME - Improved anti-HCV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HCV genotype 1a, including for example, NS4B, NS5A and NS5B. Pharmaceutical composition, recombinant vaccines comprising and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HCV are disclosed. | 04-19-2012 |
20120282217 | FOOT AND MOUTH DISEASE VIRUS (FMDV) CONSENSUS PROTEINS, CODING SEQUENCES THEREFOR AND VACCINES MADE THEREFROM - Provided herein is a nucleic acid comprising consensus amino acid sequence of foot-and-mouth disease FMDV VP1-4 coat proteins of FMDV subtypes A, Asia 1, C, O, SAT1, SAT2, and SAT3 as well as plasmids and vaccines expressing the sequences. Also provided herein is methods for generating an immune response against one or more FMDV subtypes using the vaccine as described above as well as methods for deciphering between vaccinated mammals with the vaccine and those that are infected with FMDV. | 11-08-2012 |
20130004529 | VACCINES AND METHODS FOR USING THE SAME - Improved anti-HIV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus sequences for HIV Subtype A Envelope protein, those having consensus sequences for HIV Subtype B Envelope protein, those having consensus sequences for HIV Subtype C Envelope protein, those having consensus sequences for HIV Subtype D Envelope protein, those having consensus sequences for HIV Subtype B consensus Nef-Rev protein, and those having consensus sequences form HIV Gag protein subtypes A, B, C and D. Improved anti-HPV immunogens and nucleic acid molecules that encode them; improved anti-HCV immunogens and nucleic acid molecules that encode them; improved hTERT immunogens and nucleic acid molecules that encode them; and improved anti-Influenza immunogens and nucleic acid molecules that encode them are disclosed as well methods of inducing an immune response in an individual against HIV, HPV, HCV, hTERT and Influenza are disclosed. | 01-03-2013 |
20130052222 | INFLUENZA NUCLEIC ACID MOLECULES AND VACCINES MADE THEREFROM - Provided herein are nucleic acid sequences that encode novel consensus amino acid sequences of HA hemagglutinin, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an immune response against one or more Influenza A serotpyes using the vaccines that are provided. | 02-28-2013 |
20130209395 | NUCLEIC ACID MOLECULE ENCODING HEPATITIS B VIRUS CORE PROTEIN AND SURFACE ANTIGEN PROTEIN AND VACCINE COMPRISING THE SAME - Provided herein are nucleic acid sequences encoding hepatitis B virus (HBV) core proteins, surface antigen proteins, fragments and combinations thereof as well as genetic constructs/vectors and vaccines that express said protein sequences. These vaccines are able to induce an immune response peripherally and in the liver by recruiting both cellular and humoral agents. Also provided are methods for prophylactically and/or therapeutically immunizing individuals against HBV. The combination vaccine can also be used for particular design vaccines for particular levels of immune responses to HBV challenge. | 08-15-2013 |
20130273112 | CONSENSUS ANTIGEN CONSTRUCTS AND VACCINES MADE THEREFROM, AND METHODS OF USING THE SAME TO TREAT MALARIA - Provided herein is consensus amino acid sequences of | 10-17-2013 |
20130302361 | CONSENSUS PROSTATE ANTIGENS, NUCLEIC ACID MOLECULE ENCODING THE SAME AND VACCINE AND USES COMPRISING THE SAME - Provided herein are consensus amino acid sequences of prostate antigens that are capable of breaking tolerance in a targeted species, including PSA, PSMA, STEAP and PSCA antigens. Also provided are nucleic acid sequences that encode one or more consensus amino acid sequences of prostate antigens PSA, PSMA, STEAP and PSCA, as well genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an autoimmune response against prostate cancer cells by administering one or more of the vaccines, proteins, and/or nucleic acid sequences that are provided. | 11-14-2013 |
20140023613 | Nucleic Acid Molecule Encoding Hepatitis B Virus Core Protein And Vaccine Comprising The Same - Provided herein are nucleic acid sequences that encode novel consensus amino acid sequence of HBV core protein, as well as genetic constructs/vectors and vaccines that express said protein sequences. Also provided herein are methods for generating an immune response against HBV using the nucleic acid sequences that are provided. | 01-23-2014 |
20140186384 | VACCINES AND METHODS FOR USING THE SAME - Improved anti-HIV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus sequences for HIV Subtype A Envelope protein, those having consensus sequences for HIV Subtype B Envelope protein, those having consensus sequences for HIV Subtype C Envelope protein, those having consensus sequences for HIV Subtype D Envelope protein, those having consensus sequences for HIV Subtype B consensus Nef-Rev protein, and those having consensus sequences form HIV Gag protein subtypes A, B, C and D. Improved anti-HPV immunogens and nucleic acid molecules that encode them; improved anti-HCV immunogens and nucleic acid molecules that encode them; improved hTERT immunogens and nucleic acid molecules that encode them; and improved anti-Influenza immunogens and nucleic acid molecules that encode them are disclosed as well methods of inducing an immune response in an individual against HIV, HPV, HCV, hTERT and Influenza are disclosed. | 07-03-2014 |
20140341941 | VACCINES AND METHODS FOR USING THE SAME - Improved anti-HIV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus sequences for HIV Subtype A Envelope protein, those having consensus sequences for HIV Subtype B Envelope protein, those having consensus sequences for HIV Subtype C Envelope protein, those having consensus sequences for HIV Subtype D Envelope protein, those having consensus sequences for HIV Subtype B consensus Nef-Rev protein, and those having consensus sequences form HIV Gag protein subtypes A, B, C and D. Improved anti-HPV immunogens and nucleic acid molecules that encode them; improved anti-HCV immunogens and nucleic acid molecules that encode them; improved hTERT immunogens and nucleic acid molecules that encode them; and improved anti-Influenza immunogens and nucleic acid molecules that encode them are disclosed as well methods of inducing an immune response in an individual against HIV, HPV, HCV, hTERT and Influenza are disclosed. | 11-20-2014 |
20150017197 | HCV VACCINES AND METHODS FOR USING THE SAME - Improved anti-HCV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HCV genotype 1a/1b NS3 and NS4A. Pharmaceutical composition, recombinant vaccines comprising and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HCV are disclosed. | 01-15-2015 |
20150328298 | WT1 Vaccine - Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode a mutated WT1 antigen. Vectors, compositions and vaccines comprising one or more nucleic acid sequences that encode a mutated WT1 antigen are disclosed. Methods of treating an individual who has a WT1-expressing tumor and methods of preventing a WT1-expressing tumor are disclosed. Mutated WT1 antigen is disclosed. | 11-19-2015 |
20160030548 | Influenza Nucleic Acid Molecules And Vaccines Made Therefrom - Provided herein are nucleic acid sequences that encode novel consensus amino acid sequences of HA hemagglutinin, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an immune response against one or more Influenza A serotpyes using the vaccines that are provided. | 02-04-2016 |
Patent application number | Description | Published |
20150150957 | Consensus Prostate Antigens, Nucleic Acid Molecule Encoding The Same And Vaccine And Uses Comprising The Same - Provided herein are consensus amino acid sequences of prostate antigens that are capable of breaking tolerance in a targeted species, including PSA, PSMA, STEAP and PSCA antigens. Also provided are nucleic acid sequences that encode one or more consensus amino acid sequences of prostate antigens PSA, PSMA, STEAP and PSCA, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an autoimmune response against prostate cancer cells by administering one or more of the vaccines, proteins, and/or nucleic acid sequences that are provided. | 06-04-2015 |
20150328298 | WT1 Vaccine - Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode a mutated WT1 antigen. Vectors, compositions and vaccines comprising one or more nucleic acid sequences that encode a mutated WT1 antigen are disclosed. Methods of treating an individual who has a WT1-expressing tumor and methods of preventing a WT1-expressing tumor are disclosed. Mutated WT1 antigen is disclosed. | 11-19-2015 |
20160022802 | Novel Vaccines Against Multiple Subtypes Of Dengue Virus - An aspect of the present invention is related to nucleic acid constructs capable of expressing a polypeptide, such as a consensus dengue prME that elicits an immune response in a mammal against more than one subtype of dengue virus, and methods of use thereof. Additionally, there are DNA plasmid vaccines capable of generating in a mammal an immune response against a plurality of dengue virus subtypes, comprising a DNA plasmid and a pharmaceutically acceptable excipient, and methods of use thereof. The DNA plasmid is capable of expressing a consensus dengue antigen in a cell of the mammal in a quantity effective to elicit an immune response in the mammal that is cross reactive against all 4 dengue subtypes. | 01-28-2016 |
20160030536 | Cancer Vaccines And Methods Of Treatment Using The Same - Disclosed herein are compositions and methods for treating cancer and in particular vaccines that treat and provide protection against tumor growth. | 02-04-2016 |
20160030557 | Vaccines Having an Antigen and Interleukin-23 As An Adjuvant - Disclosed herein is a vaccine comprising an antigen and IL-23. Also disclosed herein are methods for increasing an immune response in a subject. The methods may comprise administering the vaccine to the subject in need thereof. | 02-04-2016 |
20160038584 | Influenza Nucleic Acid Molecules And Vaccines Made Therefrom - Provided herein are nucleic acid sequences that encode novel consensus amino acid sequences of HA hemagglutinin and/or influenza B hemagglutinin, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an immune response against one or more influenza A serotypes and/or influenza B serotypes, or combinations thereof, using the vaccines that are provided. | 02-11-2016 |
20160039886 | Foot and Mouth Disease Virus (FMDV) Consensus Proteins, Coding Sequences Therefor and Vaccines Made Therefrom - Provided herein is a nucleic acid comprising consensus amino acid sequence of foot-and-mouth disease FMDV VP1-4 coat proteins of FMDV subtypes A, Asia 1, C, O, SAT1, SAT2, and SAT3 as well as plasmids and vaccines expressing the sequences. Also provided herein is methods for generating an immune response against one or more FMDV subtypes using the vaccine as described above as well as methods for deciphering between vaccinated mammals with the vaccine and those that are infected with FMDV. | 02-11-2016 |
Patent application number | Description | Published |
20090028862 | Emmprin antagonists and uses thereof - EMMPRIN (Extracellular Matrix Metalloproteinase Inducer) antagonists, such as antibodies, including specified portions or variants, siRNA, shRNA, antisense and DNAzymes, can be used to treat pathological processes associated with proliferative diseases, such as cancer, by specifically preventing or inhibiting the ability of proliferating tissue to develop a blood supply. | 01-29-2009 |
20110200627 | ANTI-CD147 ANTIBODIES, METHODS AND USES - The present invention provides antibodies immunospecific for human CD 147 capable of blocking bioactivity of CD 147 associated with malignant disease such as the stimulation of MMPs from fibroblast cells by tumor cells, the release of VEGF, and the promotion of angiogenesis. The antibodies of the present invention of are useful in treating malignant disease and those diseases in which CD 147 activity is plays a pathogenic role, such as diseases of the eye, lung, and cardiovascular system. | 08-18-2011 |
20140079711 | ANTI-CD147 ANTIBODIES, METHODS AND USES - The present invention provides antibodies immunospecific for human CD147 capable of blocking bioactivity of CD147 associated with malignant disease such as the stimulation of MMPs from fibroblast cells by tumor cells, the release of VEGF, and the promotion of angiogenesis. The antibodies of the present invention of are useful in treating malignant disease and those diseases in which CD147 activity is plays a pathogenic role, such as diseases of the eye, lung, and cardiovascular system. | 03-20-2014 |
20140356882 | NON-INVASIVE ENZYME SCREEN FOR TISSUE REMODELLING-ASSOCIATED CONDITIONS - Methods and kits for diagnosing the presence of and prognosing the appearance of tissue remodelling-associated conditions, involving the presence of enzyme complexes in a biological sample, are disclosed. In particular, the method pertains to diagnosing the presence of or prognosing appearance of metastatic cancer by the identification of high molecular weight enzyme complexes comprising MMPs. | 12-04-2014 |
Patent application number | Description | Published |
20140294841 | T CELL RECEPTOR-LIKE ANTIBODIES SPECIFIC FOR A WTI PEPTIDE PRESENTED BY HLA-A2 - The present invention provides antigen binding proteins that specifically bind to Wilms' tumor protein (WT1), including humanized, chimeric and fully human antibodies against WT1, antibody fragments, chimeric antigen receptors (CARs), fusion proteins, and conjugates thereof. The antigen binding proteins and antibodies bind to HLA-A0201-restricted WT1 peptide. Such antibodies, fragments, fusion proteins and conjugates thereof are useful for the treatment of WT1 associated cancers, including for example, breast cancer, ovarian cancer, prostate cancer, chronic myelocytic leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), acute myeloid/myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). In more particular embodiments, the anti-WT1/A antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels. | 10-02-2014 |
20150259436 | T CELL RECEPTOR-LIKE ANTIBODIES SPECIFIC FOR A WTI PEPTIDE PRESENTED BY HLA-A2 - The present invention provides antigen binding proteins that specifically bind to Wilms' tumor protein (WT1), including humanized, chimeric and fully human antibodies against WT1, antibody fragments, chimeric antigen receptors (CARs), fusion proteins, and conjugates thereof. The antigen binding proteins and antibodies bind to HLA-A0201-restricted WT1 peptide. Such antibodies, fragments, fusion proteins and conjugates thereof are useful for the treatment of WT1 associated cancers, including for example, breast cancer, ovarian cancer, prostate cancer, chronic myelocytic leukemia, multiple myeloma, acute lymphoblastic leukemia (ALL), acute myeloid/myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). In more particular embodiments, the anti-WT1/A antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels. | 09-17-2015 |
Patent application number | Description | Published |
20100118436 | PROTECTIVE COATINGS FOR DATA STORAGE DEVICES - A data storage device comprising a storage medium having a recordable surface, a transducing head having a bearing surface positioned adjacent to the recordable surface of the storage medium, and at least one compound disposed between the recordable surface and the bearing surface, the at least one compound comprising at least one functional group that imparts corrosion resistance and at least one functional group that imparts lubricating properties. | 05-13-2010 |
20110117386 | MEDIA LUBRICANT FOR HIGH TEMPERATURE APPLICATION - A lubricant layer for a magnetic recording medium may include a perfluoropolyether having monomer units and end groups selected to provide high thermal stability and good reliability. | 05-19-2011 |
20110205665 | COVALENTLY BOUND MONOLAYER FOR A PROTECTIVE CARBON OVERCOAT - A magnetic data storage medium may include a substrate, a magnetic recording layer, a protective carbon overcoat, and a monolayer covalently bound to carbon atoms adjacent a surface of the protective carbon overcoat. According to this aspect of the disclosure, the monolayer comprises at least one of hydrogen, fluorine, nitrogen, oxygen, and a fluoro-organic molecule. In some embodiments, a surface of a read and recording head may also include a monolayer covalently bound to carbon atoms of a protective carbon overcoat. | 08-25-2011 |
20130337194 | COVALENTLY BOUND MONOLAYER FOR A PROTECTIVE CARBON OVERCOAT - A magnetic data storage medium may include a substrate, a magnetic recording layer, a protective carbon overcoat, and a monolayer covalently bound to carbon atoms adjacent a surface of the protective carbon overcoat. According to this aspect of the disclosure, the monolayer comprises at least one of hydrogen, fluorine, nitrogen, oxygen, and a fluoro-organic molecule. In some embodiments, a surface of a read and recording head may also include a monolayer covalently bound to carbon atoms of a protective carbon overcoat. | 12-19-2013 |
20140099518 | LUBRICANTS FOR DATA STORAGE - Disclosed herein are compounds of formula I: | 04-10-2014 |
Patent application number | Description | Published |
20100047113 | AL-SI-MG-ZN-CU ALLOY FOR AEROSPACE AND AUTOMOTIVE CASTINGS - The present invention provides an aluminum casting alloy with a composition including 4%-9% Si; 0.1%-0.7% Mg; less than or equal to 5% Zn; less than 0.15% Fe; less than 4% Cu; less than 0.3% Mn; less than 0.05% B; less than 0.15% Ti; and the remainder consisting essentially of aluminum. The inventive AlSiMg composition provides increased mechanical properties (Tensile Yield Strength and Ultimate Tensile Strength) in comparison to similiarly prepared E357 alloy at room temperature and high temperature. The present invention also includes a shaped casting formed from the inventive composition and a method of forming a shaped casting from the inventive composition. | 02-25-2010 |
20100183869 | Aluminum alloys, aluminum alloy products and methods for making the same - Decorative shape cast products and methods, systems, compositions and apparatus for producing the same are described. In one embodiment, the decorative shape cast products are produced from an Al—Ni or Al—Ni—Mn alloy, with a tailored microstructure to facilitate production of anodized decorative shape cast product having the appropriate finish and mechanical properties. | 07-22-2010 |
20120261034 | METHOD OF CREATING A CAST AUTOMOTIVE PRODUCT HAVING AN IMPROVED CRITICAL FRACTURE STRAIN - The present invention provides a casting having increased crashworthiness including an aluminum alloy of about 6.0 wt % to about 8.0 wt % Si; about 0.12 wt % to about 0.25 wt % Mg; less than or equal to about 0.35 wt % Cu; less than or equal to about 4.0 wt % Zn; less than or equal to about 0.6 wt % Mn; and less than or equal to about 0.15 wt % Fe, wherein the cast body is treated to a T5 or T6 temper and has a tensile strength ranging from 100 MPa to 180 MPa and has a critical fracture strain greater than 10%. The present invention further provides a method of forming a casting having increased crashworthiness. | 10-18-2012 |
20120261035 | HIGH STRENGTH, HIGH STRESS CORROSION CRACKING RESISTANT AND CASTABLE Al-Zn-Mg-Cu-Zr ALLOY FOR SHAPE CAST PRODUCTS - The present invention provides an Al—Zn—Mg—Cu casting alloy that provides high strength for automotive and aerospace applications and optimized stress corrosion cracking resistance in highly corrosive and tensile environments. The inventive alloy composition includes about 3.5 wt. % to about 5.5 wt. % Zn; about 1.0 wt. % to about 3.0 wt. % Mg; about 0.5 wt. % to about 1.2 wt. % Cu; less than about 1.0 wt. % Si; less than about 0.30 wt. % Mn; less than about 0.30 wt. % Fe; and a balance of Al and incidental impurities. | 10-18-2012 |
20130105045 | HIGH PERFORMANCE AlSiMgCu CASTING ALLOY | 05-02-2013 |
20130160963 | Aluminum alloys, aluminum alloy products and methods for making the same - Decorative shape cast products and methods, systems, compositions and apparatus for producing the same are described. In one embodiment, the decorative shape cast products are produced from an Al—Ni or Al—Ni—Mn alloy, with a tailored microstructure to facilitate production of anodized decorative shape cast product having the appropriate finish and mechanical properties. | 06-27-2013 |
20150122660 | ALUMINUM ALLOYS, ALUMINUM ALLOY PRODUCTS AND METHODS FOR MAKING THE SAME - Decorative shape cast products and methods, systems, compositions and apparatus for producing the same are described. In one embodiment, the decorative shape cast products are produced from an Al—Ni or Al—Ni—Mn alloy, with a tailored microstructure to facilitate production of anodized decorative shape cast product having the appropriate finish and mechanical properties. | 05-07-2015 |
20150247229 | HIGH STRENGTH, HIGH STRESS CORROSION CRACKING RESISTANT AND CASTABLE AL-ZN-MG-CU-ZR ALLOY FOR SHAPE CAST PRODUCTS - The present invention provides an Al—Zn—Mg—Cu casting alloy that provides high strength for automotive and aerospace applications and optimized stress corrosion cracking resistance in highly corrosive and tensile environments. The inventive alloy composition includes about 3.5 wt. % to about 5.5 wt. % Zn; about 1.0 wt. % to about 3.0 wt. % Mg; about 0.5 wt. % to about 1.2 wt. % Cu; less than about 1.0 wt. % Si; less than about 0.30 wt. % Mn; less than about 0.30 wt. % Fe; and a balance of Al and incidental impurities. | 09-03-2015 |
20150259774 | METHODS FOR ARTIFICIALLY AGING ALUMINUM-ZINC-MAGNESIUM ALLOYS, AND PRODUCTS BASED ON THE SAME - New methods for aging aluminum alloys having zinc and magnesium are disclosed. The methods may include first aging the aluminum alloy at a first temperature of from about 310° F. to 530° F. and for a first aging time of from 1 minute to 6 hours, and then second aging the aluminum alloy at a second temperature for a second aging time of at least 30 minutes, with the second temperature being lower than the first temperature. | 09-17-2015 |
20150315680 | 7XX ALUMINUM CASTING ALLOYS, AND METHODS FOR MAKING THE SAME - New 7xx aluminum casting alloys are disclosed. The aluminum casting alloys generally include from 3.0 to 8.0 wt. % Zn, from 1.0 to 3.0 wt. % Mg, where the wt. % Zn exceeds the wt. % Mg, from 0.35 to 1.0 wt. % Cu, where the wt. % Mg exceeds the wt. % Cu, from 0.05 to 0.30 wt. % V, from 0.01 to 1.0 wt. % of at least one secondary element (Mn, Cr, Zr, Ti, B, and combinations thereof), up to 0.50 wt. % Fe, and up to 0.25 wt. % Si, the balance being aluminum and other elements, wherein the aluminum casting alloy include not greater than 0.05 wt. % each of the other elements, and wherein the aluminum casting alloy includes not greater than 0.15 wt. % in total of the other elements. | 11-05-2015 |
20150376754 | METHODS FOR ARTIFICIALLY AGING ALUMINUM-ZINC-MAGNESIUM ALLOYS, AND PRODUCTS BASED ON THE SAME - New methods for aging aluminum alloys having zinc and magnesium are disclosed. The methods may include first aging the aluminum alloy at a first temperature of from about 330° F. to 530° F. and for a first aging time of from 1 minute to 6 hours, and then second aging the aluminum alloy at a second temperature for a second aging time of at least 30 minutes, with the second temperature being lower than the first temperature. | 12-31-2015 |